Maximizing clinical benefit with trastuzumab.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Seminars in Oncology

• Publication date

  2004-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/J.SEMINONCOL.2004.07.020PMID 15490373
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Continuation of trastuzumab beyond disease progression.

  2005cited by this paper
• Recent translational research: antiangiogenic therapy for breast cancer – where do we stand?

  2004cited by this paper
• Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.

  2004cited by this paper
• Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC)

  2004cited by this paper
• Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.

  2004cited by this paper
• Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial

  2004cited by this paper
• Optimizing treatment of HER2-positive metastatic breast cancer.

  2004cited by this paper
• A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast Cancer

  2004cited by this paper
• Multicenter phase II trial of three-weekly docetaxel and weekly trastuzumab in HER-2-overexpressing metastatic breast cancer patients: Japan East cancer center breast cancer consortium (JECBC 01 trial)

  2004cited by this paper
• Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories.

  2004cited by this paper
• A multinational phase II study of Navelbine (N) and Herceptin (H) as first-line therapy for patients with HER2-positive metastatic breast cancer (HER2+ MBC)

  2004cited by this paper
• Trastuzumab and vinorelbine combination in the treatment of metastatic breast cancer

  2004cited by this paper
• Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival.

  2004cited by this paper
• Weekly docetaxel and trastuzumab for her-2-overexpressing metastatic breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study

  2004cited by this paper
• Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.

  2004cited by this paper
• Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer.

  2004cited by this paper
• Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

  2004cited by this paper
• Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer

  2004cited by this paper
• Continuation of Trastuzumab Beyond Disease Progression: More Questions Than Answers

  2004cited by this paper
• Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

  2003cited by this paper
• Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.

  2003cited by this paper
• Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

  2003cited by this paper
• Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer.

  2003cited by this paper
• Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.

  2003cited by this paper
• Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

  2003cited by this paper
• Breast Cancer Endocrine Resistance

  2003cited by this paper
• Capecitabine/Bevacizumab Compared to Capecitabine Alone in Pretreated Metastatic Breast Cancer: Results of a Phase III Study)

  2003cited by this paper
• Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

  2003cited by this paper
• Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

  2003cited by this paper
• Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.

  2003cited by this paper
• 464 Efficacy and toxicity of docetaxel or cisplatin chemotherapy in combination with trastuzumab in the treatment of patients with chemotherapy pre-treated HER-2/neu overexpressed metastatic breast cancer

  2003cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models

  2002cited by this paper
• Fecal occult blood test for colorectal cancer screening.

  2002cited by this paper
• Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines

  2002cited by this paper
• Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results.

  2002cited by this paper
• Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer.

  2002cited by this paper
• Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.

  2002cited by this paper
• Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

  2002cited by this paper
• Current Status of HER2 Testing

  2002cited by this paper
• Combination chemotherapy for metastatic breast cancer

  2002cited by this paper
• Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial

  2002cited by this paper
• Relationship of estrogen receptor (ER) status to clinical benefit in clinical trials of herceptin

  2001cited by this paper
• Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

  2001cited by this paper
• Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.

  2001cited by this paper
• Estrogen receptor status in the Herceptin (trastuzumab) clinical trials: Incidence and relation to clinical benefit

  2001cited by this paper
• Single-Agent Gemcitabine Is Active in Previously Treated Metastatic Breast Cancer

  2001cited by this paper
• Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study.

  2001cited by this paper
• Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.

  2001cited by this paper
• Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.

  2001cited by this paper
• Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials

  2001cited by this paper
• Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study.

  2001cited by this paper
• MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells.

  2000cited by this paper
• Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.

  2000cited by this paper
• Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.

  2000cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

  1999cited by this paper
• Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.

  1999cited by this paper
• Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

  1999cited by this paper
• Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

  1998cited by this paper
• Advanced breast cancer: a phase II trial with gemcitabine.

  1995cited by this paper
• HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.

  1995cited by this paper
• Vinorelbine (Navelbine) in the treatment of breast cancer: a summary.

  1995cited by this paper
• Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

  1995cited by this paper
• The biology of erbB-2/neu/HER-2 and its role in cancer.

  1994cited by this paper
• Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

  1992cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

  1985cited by this paper
• Aldolase isozymes in cancer.

  1966cited by this paper

• Conditional control of suicide gene expression in tumor cells with theophylline-responsive ribozyme

  2016cites this paper
• Effect of neoadjuvant chemotherapy on histopathology and immunohistochemistry in breast cancer

  2015cites this paper
• Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes

  2011cites this paper
• Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer

  2009cites this paper
• Metastatic breast cancer in young woman: capecitabine monotherapy after failure of the targeted therapy - a case report

  2009cites this paper
• The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

  2009cites this paper
• HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies.

  2008cites this paper
• Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.

  2007cites this paper
• Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).

  2007cites this paper
• Prognostische Relevanz der Polokinasen in soliden Tumoren Implikationen für neue chemotherapeutische Ansätze

  2007cites this paper
• Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issues.

  2007cites this paper
• A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer.

  2007influential citation
• Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

  2007cites this paper
• HER-2/neu overexpression in invasive ductal breast cancer: An association with other prognostic and predictive factors

  2007cites this paper
• Treatment with Combinations of the Anti-HER2 Antibody Trastuzumab and Capecitabine in Advanced Metastatic Breast Cancer Patients – a Pilot Study

  2007cites this paper
• Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status

  2006cites this paper
• Development of novel therapeutic strategies that target HIF-1

  2006cites this paper
• Targeting Raf-kinase: molecular rationales and translational issues.

  2006cites this paper
• EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy.

  2006cites this paper
• Molecular Markers of Multiple Drug Resistance in Breast Cancer

  2006cites this paper
• Biomarkers and multiple drug resistance in breast cancer.

  2006cites this paper
• Trastuzumab plus estrogen suppression as salvage treatment in a case of liver failure due to metastatic breast cancer.

  2006cites this paper
• Stadienadaptierte Therapie des Mammakarzinoms

  2006cites this paper
• Molecular basis of Barrett’s oesophagus and oesophageal adenocarcinoma

  2006cites this paper
• Evidence-based treatment of metastatic breast cancer - 2006 recommendations by the AGO Breast Commission.

  2006cites this paper
• Evidence-based treatment of metastatic breast cancer – 2006 recommendations by the AGO Breast Commission

  2006cites this paper
• La thérapie ciblée en oncologie et la pointe de l’Iceberg Première partie : le récepteur épidermique humain HER/ErbB

  2006cites this paper
• Targeting the HER Family of Receptors in the Treatment of Advanced Breast Cancer

  2006cites this paper
• Das Mammakarzinom

  2005cites this paper
• Molecular Medicine: Promises, Promises?

  2005cites this paper
• Meeting Highlights2004 Highlights From: The 27th Annual San Antonio Breast Cancer Symposium; San Antonio, TX December 2004

  2005cites this paper
• The antitumor immune response in HER-2 positive, metastatic breast cancer patients

  2005cites this paper
• Monoclonal Antibodies as Therapeutic Agents: Advances and Challenges

  2005cites this paper
• Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways.

  2005cites this paper
• Phase III trials in oncology: setting standards of care?

  2005cites this paper
• Trastuzumab and Liposomal Doxorubicin in the Treatment of MCF-7 Xenograft Tumor-Bearing Mice: Combination Does Not Affect Drug Serum Levels

  2005cites this paper
• Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR).

  2005cites this paper
• Archive of SID Monoclonal Antibodies as Therapeutic Agents: Advances and Challenges

  2005cites this paper
• Optimizing treatment of HER2-positive metastatic breast cancer.

  2004cites this paper